Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2633195 | 0.83 | HTR2A (0.42) | — | |
| SCHEMBL7538162 | 0.82 | SLC6A2 (0.43) | SLC7A5OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL2628023 | 0.78 | IDO1 (0.42) | SLC6A2SLC6A4IDO1TDO2 | |
| SCHEMBL2633138 | 0.77 | OPRM1 (0.36) | SLC7A5OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL9883145 | 0.76 | SLC6A2 (0.46) | AOC3SLC6A2SLC6A4IDO1TDO2 | |
| SCHEMBL11077274 | 0.75 | IDO1 (0.52) | SLC7A5AOC3SLC6A2SLC6A4IDO1 | |
| SCHEMBL19101512 | 0.73 | OPRM1 (0.39) | SLC7A5OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL21732183 | 0.73 | OPRM1 (0.42) | OPRM1OPRD1OPRK1OPRL1AOC3 | |
| SCHEMBL21555784 | 0.73 | OPRM1 (0.39) | SLC7A5OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL2628025 | 0.73 | SLC6A2 (0.43) | SLC7A5AOC3SLC6A2SLC6A4IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8357809-B2 | Acyclic IKur inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-22 | — | — | US | disclosed |
| US-20120094983-A1 | ACYCLIC IKUR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-04-19 | — | — | US | disclosed |
| US-7915410-B2 | Acyclic IKur inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-29 | — | — | US | disclosed |
| US-20070082909-A1 | Acyclic Ikur inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-12 | — | — | US | disclosed |
| WO-2007030582-A2 | ACYCLIC IKUR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082909-A1 | Acyclic Ikur inhibitors | KCNH2, KCNJ2, KCNH3 | SLC7A5 4125/4885OPRM1 549/4885OPRD1 233/4885 |
| US-20120094983-A1 | ACYCLIC IKUR INHIBITORS | KCNH2, KCNJ2, KCNH3 | SLC7A5 4125/4885OPRM1 549/4885OPRD1 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.